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Abstract
Introduction: The global increase life expectancy and the resulting 
tooth loss has required searching for new rehabilitation alternatives 
in Dentistry. Biomaterials can be defined as any material that acts 
replacing a lost bone defect and its function. In Dentistry, many 
studies have aimed to improve bone regeneration through the use 
of BMPs for bone replacement. Objective: To review the literature 
on the use and clinical viability of human morphogenetic protein 
for the jaws reconstruction. Material and methods: The following 
databases were searched: Pubmed, Bireme, Lilacs, and Scielo and 
30 articles published between 1965 and 2013 were found using 
the following descriptors: “dental implants”, “maxillary sinus”, and 
“biocompatible materials”. Results: Several studies demonstrate the 
biological advantages of rhBMP-2 on bone regeneration of the jaws. 
In recent years, morphogenetic protein has presented a large clinical 
use. Conclusion: Despite being a high-cost biomaterial, rhBMP-2 is 









89 – RSBO. 2015 Jan-Mar;12(1):88-93
Marques et al. – Application of BMP-2 for bone graft in Dentistry
Introduction
The increased expectation of worldwide life and 
the consequent tooth loss have required more and 
more of Dentistry the search for viable alternatives 
to oral rehabilitation [20].
After the scientific evidence of osseointegration 
in the ending of the 1970s, which made viable 
Implantology, increased the interest of researchers 
in search by new natural or synthetic substances 
that could replace tissues bone lost [9]. In Dentistry 
autogenous bone is the most useful tissue used in 
pre-prosthetic surgery and rehabilitation treatment 
of bone defects, thereby contributing to the function 
and aesthetics [8].
Biomaterials can be defined as “any material, 
natural or synthetic, that acts in tissues/organs in 
order to replace the bone defect lost and s function” 
[13]. The biomaterials may be considered autogenous 
when the bone is taken from the individual to be 
treated; halogens, when the gathered from another 
individual of the same species, and heterogeneous, 
when taken from other species [6].
The human bone morphogenetic protein 
(rhBMP) developed by genetic engineering, was 
isolated by Urist, in 1965, and it is considered 
a substance capable of inducing differentiation 
of mesenchymal stem cells into osteoblasts, the 
cells that are responsible for the synthesis of bone 
matrix. Research given to BMPs the capacity of 
fracture repair, osteogenic, osteoinductive, and 
osteoconductive potential of the graft [22].
In Dentistry, many studies have aimed to 
improve bone regeneration through the use of BMPs 
for bone replacement. Because of the osteoinductive 
capacity, BMPs have various application possibilities 
in the Dentistry, raising great interests in various 
specialties, especially in the Implantology, assisting 
in osseointegration [30].
The aim of this study was to conduct a literature 
review on the use and clinical viability of human 




The success of rehabilitation with dental 
implants is directly related to the amount of bone 
tissue of the patient. As the resorption is something 
common mainly in older patients, it is increasingly 
common the application of techniques for maxillary 
sinus augmentation by using grafts. In addition, 
tumors, congenital deformities, trauma, among 
others, may require the need for reconstruction 
of jaws [14, 25]. 
The autogenous graft type, considered the gold 
standard, is best used for the rehabilitation of the 
jaws, because of their osteogenic, osteoconductive, 
and osteoinductive properties. However, autogenous 
grafts require a second surgical site, and the bone 
is removed normally from the mandibular ramus, 
chin, skullcap, iliac, or tibia. The need for a second 
surgical site makes the surgical process more 
complex with side effects to the patient [27].
The homogenous and heterogeneous grafts 
lack of living cells, since pass through a process 
of purification, but may show osteoconductive or 
osteoinductive features. The great advantage of 
these two types of graft is that they do not need a 
second surgical site, which makes the reconstructive 
procedure faster, safer, and less complex [8].
The biomaterial for optimal bone grafting should 
be osteogenic, osteoinductive, osteoconductive, be 
biologically inert, and have fast revascularization 
activity [8].
History and classification of rhBMPs
Urist [28] conducted an innovative experiment 
and with very promising results, in which muscle 
tissue was implanted on rabbit leg in demineralized 
bone matrix. After 3 weeks, it was observed the 
formation of ectopic bone. Thus, it was concluded 
that the bone matrix contained some important 
factor capable of performing a self-induction. This 
factor was called bone morphogenetic protein 
(BMP). The initial advancement led to the study 
of several researchers seeking to isolate and clone 
the inductive entity. Actually it is known that it is 
not only one but several growth factors.
Currently, despite the knowledge of the capacity, 
by manipulation of the medium, of differentiating 
in osteoblasts, the mechanisms that govern these 
actions are not fully elucidated [21]. The molecular 
bases of bone morphogen protein, which mostly 
belong to the superfamily of transformation growth 
factor β (TGF-β) accounts for these mechanisms 
[15]. It is known that this set of proteins is made 
up of 12 different types of inducing molecules, 
each of which develops a specific function, and 
may also perform joint actions by interacting 
among each other. Thus, they are classified as: 
BMP 1, 2, and 3 (osteogenin); 4 to 7 (Osteogenic 
Protein-1); 8 (osteogenic protein-2 ca); 9-12 in 
isolated group [23].
90 – RSBO. 2015 Jan-Mar;12(1):88-93
Marques et al. – Application of BMP-2 for bone graft in Dentistry
Mechanisms of rhBMPs
The rhBMPs may be defined as signaling 
glycoproteins, and members of the superfamily 
of growth factor β (TGF-β), capable of recruiting 
osteoprogenitor cells to sites of bone formation, and 
are macromolecules of essential role in the repair 
process and bone growth. The osteoinductive action 
of autogenous and demineralized homogenous bone 
matrix graft may also be attributed to that protein. 
Nakashima [15] found that these proteins stimulated 
mitosis of mesenchymal stem cells because they 
have the ability to turn on specific receptors, as 
serine/threoninacinase and induce differentiation 
of precursor cells of osteodentin tissue, which 
are osteodentinocytes. The osteodentin, major 
component of dental matrix newly formed, seems 
to have a coadjutant role in the differentiation of 
osteoblasts, because in its absence, promising 
results were not obtained [15, 24].
Accordingly, the rhBMPs can be used in 
the reconstruction of bone tissue, having well-
established benefit in Dentistry and Orthopedics, 
since they are able to induce migration, proliferation 
and differentiation of mesenchymal stem cells into 
secretory osteoblasts and form bone [7].
Brand and product
Bone morphogenetic proteins are obtained by 
genetic engineering techniques. They are produced by 
genetic recombination in Escherichia coli and sold 
as lyophilized powder in sterile vial, ready for use. 
This lyophilized powder associated with a vehicle 
benefits the bone-implant interface, accelerating 
osseointegration [12, 19].
The rhBMP commercially available and approved 
by FDA in the United States currently are: rhBMP-
2 Infuse (Medtronic Sofamor Danek, Memphis, 
Tennessee) and OP1 (Stryker Biotech, Hopkinton, 
MA). Other BMP products are currently being 
evaluated for commercial use include BMP-X (Sulzer 
Biologics, Wheat Ridge, Colorado), BMP -9, and 
combinations of BMP animal and human [1].
Hu et al. [11] stated that BMP-9 is one of 
the most potent forms between 12 rhBMP types 
in the induction of osteogenic differentiation of 
mesenchymal progenitor cells, both in vitro and in 
vivo, through the regulation of several major targets 
during differentiation of the rhBMP-9 osteoblasts 
induced.
Application Form
A bone graft BMPs kit is used for the repair 
and bone growth, and after handling BMP is directly 
placed on the site. In addition, carrier agents are 
needed to make the diffusion agents among cells 
to facilitate osteoinduction [14].
The optimum carrier substrate should provide 
the following characteristics: relative insolubility 
under physiological conditions; to be biodegradable; 
to protect the tissue against proteolytic activities; 
to function as substrate for cell adhesion and 
proliferation; to be inert immunologically; to obtain 
the slow and controlled release of rhBMP through 
controlled biological degradation; and to have 
mechanic stability to unite bone defects [10]. 
Among the biomaterials tested as carriers, 
various extracellular matrix components may be 
used alone or in combination, for example: collagen, 
fibronectin, glycosaminoglycans, calcium hydroxide, 
and calcium phosphate [10].
The spongy bone graft has been considered an 
ideal carrier. It acts as a scaffold promoting early 
vascularization and osteoinduction, and provides 
osteogenic cells, is biocompatible, and has the 
ability to adapt to bone failures [14].
A rhBMP-2 Infuse® is marketed in package 
containing all the components needed to prepare 
the bone inducing component Infuse®: rhBMP-2 
lyophilized powder to be reconstituted, sterile 
water, absorbable collagen sponge, syringe with 
needles, and preparation instructions. The number 
of each item may vary depending on the size to 
be used. The rhBMP-2 is provided as a lyophilized 
powder in vials with 4.2 mg or 12 mg of protein. 
After proper reconstitution, both sets result in the 
same formulation and concentration (1.5 mg/cc) of 
rhBMP-2 [5].
According to the manufacturer, the Infuse® bone 
graft should be prepared at surgery time, always 
30 minutes before the application of the material 
in the surgical site. With the aid of syringe and 
needle, the sterile water must be removed from 
the bottle and inject in the vial containing rhBMP-
2, then mix slowly without stirring and leave at 
least 15 minutes at rest for complete dissolution. 
The original packaging IS opened and puts the 
absorbable collagen sponge in sterile field. With 
the aid of the second syringe, the reconstituted 
bone graft is removed from ampule and is applied 
uniformly in the sponges. The moist sponges should 
rest for at least 15 minutes (time for incorporation 
of the protein to the sponge) and must be used 
within two hours (for avoiding the drying of the 
sponge) [5].
Advantages of rhBMP-2
The regenerative activity and bone induction of 
rhBMP-2 has been extensively studied by researchers 
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of Genetic Engineering, which its advancement 
allowed the characterization, cloning and large-
scale commercial production. Studies evaluating the 
association of rhBMPs with biomaterials showed to 
be a viable and effective alternative to make bone 
regeneration ease [30].
Since the discovery of rhBMP, several studies 
have demonstrated the biological advantages of 
rhBMP-2 and significant rehabilitation on bone 
formation in studies both on rats and humans, 
which takes about six months [29].
A study evaluated the applicability of rhBMP-2 
in a collagen sponge after it had been applied in 
bone defects. It was observed that after 12 weeks 
the mean neoformation and bone density in the 
group that received rhBMP-2 was nearly 4 times 
greater than that of the control group [18].
In recent years, the morphogenetic protein has 
been highly successful for the reconstruction of 
the jaw defects and large defects of the face. The 
great advantage compared to autogenous bone is 
that it eliminates the need for a second surgical 
site, which considerably increased the surgery time, 
and bone removal from another area as the iliac, 
tibial or skullcap [2, 14].
Clinical trials that studied the effect of BMP-2 
in collagen sponges regarding to bone deposition 
detected a significant growth and bone formation in 
the surgery of maxillary sinus lifting. In addition, 
other studies show that rhBMP-2 has been successful 
in complex treatments of the face, as congenital 
jaw defects in alveolar atrophy, and maxillary 
fissures [18].
The association of rhBMP-2 with homogenous 
graft also showed favorable clinical outcomes in 
peri-implant bone resorption [18].
Disadvantages of rhBMP-2
The morphogenetic proteins are readily 
diffusible and soluble in water, so they must be 
applied with a carrier so that an effective inducing 
effect is established [10].
The carrier systems for rhBMPs still require 
research to optimize their formulations. The use of 
collagen isolated or associated with carrier systems, 
although widely used, has some disadvantages that 
must be observed, such as poor mechanical stability, 
immune response and potential for transmission 
of viral antigens [10].
When rhBMPs are compared to PRPs (platelet 
rich plasma), the main disadvantages of the 
morphogenetic proteins are the high cost and the 
need to use a carrier agent [12].
Although the studies show good results in the 
process of the osteoinduction, they do not quantify 
the value of the speed increase of the process when 
using rhBMPs [12].
When working with rhBMP, caution should 
be taken, because it is a very sensitive material 
regarding to technique, any error in handling can 
lead to unsatisfactory results. The effectiveness of 
this material may be affected by factors such as 
amount, qualitative composition, possible presence 
of inhibitors, processing and storage. And, for the 
inductive result, the dose, concentration, and time 
of action of rhBMPs are influencing factors [26].
The multiple rhBMPs forms already identified 
demand new studies, which may happen slowly, 
due to the high costs involved in research with 
morphogenetic proteins. Such researches are needed 
to determine the choice for the most appropriate 
factor for each therapy and also enable the direction 
of new techniques [10].
The literature presents many advantages in the 
use of various forms of morphogenetic proteins, 
but the studies are still few compared to various 
therapeutic applications of rhBMP, beyond the 
specialties of Dentistry. This may occur because 
of the high costs needed to develop research with 
this material.
Discussion 
Undoubtedly, the advances in Genetic Engineering 
have brought new viable and effective alternatives for 
Dentistry. These included, biomaterials stand out, 
and researches associated with the use of rhBMPs 
emerge as another option for new bone formation. 
Among the group consisting of the rhBMP proteins, 
rhBMP-2 showed higher expression in human bone 
in scientific research [13].
Yonezawa et al. [29] and Padovan et al. [18], 
in studies with the use of morphogenetic proteins, 
demonstrated positive results in terms of bone 
formation and density, implying a significant 
rehabilitation for critical defects and alveolar bone 
grafting.
In another study, in which the bone formation 
was investigated in the maxillary sinus of goats 
using rhBMP-2 in an absorbable collagen sponge, 
the osteoinductive capacity of the protein was proven 
without side effects [13]. The authors also claim 
that rhBMP-2 really is an alternative for maxillary 
sinus lifting in humans.
A clinical trial with 160 patients, in which 
the effectiveness of rhBMP-2 was compared to 
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autogenous bone in maxillary sinus lifting and 
installation of dental implants, concluded that 
bone formation in height was the same in both 
groups [16].
The study of Cruz et al. [4] found that progenitor 
cells derived from human adipose tissue expressed 
rhBMP-4, endogenous rhBMP-7. On the other hand, 
the supplementation of progenitor cells derived 
from adipose tissue with rhBMP-2 did not increase 
the level of osteogenic markers at the initial phase 
(activity of alkaline phosphatase), at the intermediate 
phase (osteonectin and osteocalcin), or final phases 
(calcium deposition), suggesting that the exogenous 
addition of rhBMP-2 did not improve the process 
of osteogenesis in vitro of progenitor cells derived 
from adipose tissue human.
Oliveira et al. [17] evaluated the healing of 
tibial defect induced in dogs. Eighteen adult dogs 
were divided into three groups of six dogs each. 
The defects were filled with bone collagen sponge. 
In group 1 (G1), a sponge added with 0.9% saline 
solution was used; in G2, a sponge added with 
processed autologous mononuclear bone marrow 
cells was used; and in G3, a sponge added 
with processed autologous mononuclear bone 
marrow cells and rhBMP-2 was used. Although G2 
presented a better result than G1, bone growth in 
G3 (supplemented with rhBMP-2) showed the best 
results in the analyses of 15 and 30 days after the 
start of the experiment. Forty-five days later, 50% 
of this group of dogs already had complete healing 
of the bone defect [17].
Despite the excellent results obtained in various 
researches and clinics using rhBMP-2, little is 
reported in the literature on the adverse effects and 
complications that can occur when using this graft 
material. Carragee et al. [3] criticized the industry 
to report that it is a product that has no risk, even 
when several studies suggest the opposite. The 
same study did a survey on adverse effects using 
rhBMP-2 in human spinal surgeries and obtained 
as possible complications: infection, malignancy 
risk at high doses, morbidity (pain and functional 
impairment), ectopic bone formation, retrograde 
ejaculation and urogenital adverse effects.
Conclusion
The morphogenetic proteins have major clinical 
applications; however, research is still necessary to 
establish proper techniques for the use of rhBMP 
s for each specific case. In Implantology, rhBMPs 
emerged as the major substitute to autogenous 
bone grafting, especially for its osteoinductive 
characteristics and for dispensing the need of a 
second surgical site to the patient. Notwithstanding, 
the high costs of this biomaterial still prevent 
many individuals to benefit and that researches 
are developed.
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